Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03838445 · ClinicalTrials.gov registry record · NA

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

A NA study of Pulmonary Arterial Hypertension, sponsored by V-Wave.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
5
Study locations

NCT03838445 is a NA study of Pulmonary Arterial Hypertension that is actively recruiting participants, run by V-Wave. The registered enrollment target is 20 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03838445, a NA study of Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by V-Wave.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
5
Study locations

Study Summary

The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

Interventions

  • DEVICE V-Wave Interatrial Shunt

Study Locations (5)

California

  • Keck Medical Center of USC - Los Angeles
  • University of California, San Francisco - San Francisco

Other

  • Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval - Québec
  • Instituto Nacional de Cardiologia - Mexico City

Ohio

  • The Ohio State University Wexner Medical Center - Davis Heart & Lung Research Institute - Columbus

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2020-02-14
Est. Completion 2026-12-31
Phase NA

Sponsor

V-Wave

2 total trials

What the Registry Record Tells You About NCT03838445

The ClinicalTrials.gov registry entry for NCT03838445 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower). The listed sponsor is V-Wave, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which V-Wave Interatrial Shunt is the first listed.

NCT03838445 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Other, Ohio.

Frequently Asked Questions

What is clinical trial NCT03838445 about?

NCT03838445 is a clinical study titled "Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)". The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

What is the current status of trial NCT03838445?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2020-02-14. Estimated completion is 2026-12-31.

What conditions does trial NCT03838445 study?

This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.

What interventions are being tested in trial NCT03838445?

The interventions under investigation include: V-Wave Interatrial Shunt (DEVICE).

Who is sponsoring clinical trial NCT03838445?

This trial is sponsored by V-Wave, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03838445 being conducted?

This trial has 5 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Arterial Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.